GSA Capital Partners’s Sutro Biopharma STRO Stock Holding History

GSA Capital Partners’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$656K	Sell	19,749 -6,073	-24%	-$189K	0.04%	820
2026 Q1	$643K	Sell	25,822 -63,245	-71%	-$1.14M	0.04%	763
2025 Q4	$1.03M	Buy	89,067 +71,583	+409%	+$679K	0.09%	348
2025 Q3	$152K	Buy	+17,484	New	+$149K	0.01%	1480
2024 Q3	–	Sell	-23,540	Closed	-$690K	–	1994
2024 Q2	$690K	Buy	+23,540	New	+$931K	0.05%	767
2023 Q4	–	Sell	-6,775	Closed	-$235K	–	1908
2023 Q3	$235K	Buy	+6,775	New	+$295K	0.02%	1212
2023 Q2	–	Sell	-2,059	Closed	-$95K	–	1931
2023 Q1	$95K	Sell	2,059 -2,344	-53%	-$149K	0.01%	1368
2022 Q4	$356K	Sell	4,403 -12,151	-73%	-$844K	0.04%	816
2022 Q3	$919K	Sell	16,554 -5,258	-24%	-$311K	0.12%	198
2022 Q2	$1.14M	Buy	21,812 +18,268	+515%	+$1.02M	0.17%	98
2022 Q1	$291K	Sell	3,544 -3,597	-50%	-$342K	0.04%	913
2021 Q4	$1.06M	Buy	+7,141	New	+$1.28M	0.13%	184

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

GSA Capital Partners's STRO Position: Q2 2026 in Review

GSA Capital Partners reduced its Sutro Biopharma (STRO) stake by 24% in Q2 2026, selling an estimated $189K and leaving 19,749 shares worth $656K. The position accounts for 0.04% of the portfolio, ranked #820.

GSA Capital Partners first reported a position in STRO in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.14M in Q2 2022. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

GSA Capital Partners held 19,749 shares of Sutro Biopharma worth $656K as of Q2 2026.
GSA Capital Partners sold 6,073 Sutro Biopharma shares in Q2 2026, an estimated $189K.
Sutro Biopharma made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #820 holding.
GSA Capital Partners first reported a position in Sutro Biopharma in Q4 2021 and has held it in 12 quarters since.
GSA Capital Partners's Sutro Biopharma position peaked at $1.14M in Q2 2022.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.